Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers

NCT01240148 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral Neuropathic Pain
Nociceptive Pain

Interventions

DRUG: AZD3161
DRUG: Lidocaine
DRUG: AZD3161 Placebo

Sponsor

AstraZeneca